STE
NYSE · USDSTERIS plc
Healthcare · Medical - Specialties
CEO Daniel A. Carestio
Employees 17,937
R&D / revenue 1.9%
Last price
$222.66−0.74%last session
Market cap
$21.7B
P/E (TTM)
27.2x
From 52w high
−17.4%
From 52w low
+14.1%
1-year return
−7.1%
RSI 14 · vs SMA200
62.1 · −1.5%
IS score
68.5/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)
One year, rebased to 100
STE SPY XLV (sector ETF) · weekly closesScore DNA
Each bar is a 0-100 score within the scored universe53Profitability
63Growth
51Value
90Momentum
100Risk (safety)
81Quality
72Balance sheet
74Earnings quality
Flags
Strengths
✓ Piotroski 8+✓ Congress buying
Warnings
None of the computed warning flags fires for STE (Altman, Beneish, accruals, FCF, dilution).
Observations
Moat model: Narrow, Efficient ScalePiotroski 8 / 9Altman Z 5.0Beta 0.912 of 4 smart-money sources active
Smart-money strip
Each disclosure source on its own window. Filings coinciding is not coordination.INSForm 4 · 180 days
Insider open-market buys
0
5 open-market sales, $2.5M
Form 144 notices (12m): 10, $10.8M proposed, not confirmed sales
CONGSTOCK Act · 180 days
Congressional purchases
12
Last disclosed purchase 2026-09-11
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2025-12-31
Net change in institutional holders
−1,351
3 new holders, 0 closed
13 filers hold 0.3% · 2 added, 14 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+187
998 funds adding shares
811 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
42.5%
20-day avg 59.0%, 50-day avg 64.6%
Latest 16.5 pp under its 20-day average · a flow, not short interest
Key financials · FY2026
USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.Income statement
Revenue$5.9B
Revenue growth YoY+8.7%
Gross margin44.2%
Operating income$1.1B
Operating margin18.6%
Net income$785.1M
Net margin13.2%
EPS (diluted)$7.93
Cash flow
Operating cash flow$1.3B
Capital expenditure$369.0M
Free cash flow$972.4M
FCF conversion (FCF / OCF)72.5%
Stock-based compensation$61.7M
FCF less SBC$910.7M
Buybacks$235.5M
Dividends$241.8M
Balance sheet & returns
Cash & short-term investments$439.6M
Total debt$2.0B
Net debt$1.5B
Shareholders' equity$7.2B
Goodwill & intangibles$5.8B
Debt / equity0.28
ROE (TTM)11.3%
ROIC (TTM)8.7%
Operating margin by fiscal year
Revenue $4.2B (FY2022) to $5.9B (FY2026), a 8.9% CAGR.
Valuation
P/E (TTM)27.2x
EV / EBITDA14.3x
Price / sales3.60x
Price / FCF23.5x
FCF yield4.26%
Buyback yield1.08%
SBC / revenue1.0%
Price / book3.02x
Forward P/E FY202719.9x
Forward P/E FY202818.2x
Forward multiples divide today's price by Street EPS estimates. Street mean target $275.00 across 1 analysts last quarter is theirs, not ours.
STE vs industry median
49 companies in Medical - Specialties
STE (TTM)Industry median
Asset turnover 0.56 vs industry 0.52 · financial leverage 1.49
Earnings delivery
Next report 2026-11-04 · consensus EPS $2.6867%
beat rate, 8 of 12 quarters
+2.4%
median EPS surprise
4
longest beat streak
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-11-07 to 2026-08-05. Bars cap at ±60%.
Peers
Market-cap band, not the industry cohort above| Company | Mkt cap | P/E | ROE | Net margin | Rev growth | 12m return |
|---|---|---|---|---|---|---|
| STE STERIS plc | $21.7B | 27.2x | 11.3% | 13.3% | +8.7% | −7.1% |
| ALC Alcon Inc. | $32.0B | 50.9x | 2.9% | 0.0% | +7.8% | −12.2% |
| THC Tenet Healthcare Corporation | $21.5B | 10.2x | 53.3% | 14.7% | +5.4% | +34.2% |
| VTRS Viatris Inc. | $21.4B | n/m | -2.8% | -3.2% | +4.4% | +87.0% |
| GH Guardant Health, Inc. | $21.3B | n/m | 171.6% | -35.9% | +42.7% | +135.1% |
| INSM Insmed Incorporated | $21.0B | n/m | -87.2% | -3.1% | +185.8% | — |
| GMAB Genmab A/S | $22.8B | 29.4x | 4.0% | 26.2% | −77.7% | — |
| UTHR United Therapeutics Corporat | $22.9B | 17.6x | 19.3% | 42.5% | +2.5% | — |
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.
Recent 8-K filings
2026-10-13Material Agreement
2026-08-06Officer/Director Change
2026-08-06Shareholder Vote
2026-08-05Earnings Release; Exit/Disposal Costs; Exhibits
2026-05-07Officer/Director Change; Regulation FD; Exhibits
2026-04-06Officer/Director Change
Context
Shares outstanding97,500,100
Free float99.7%
Institutional ownership0.3%
Beta0.91
Dividend yield1.16%
Last dividend$0.69 on 2026-09-04
50 / 200-day average$221.53 / $226.40
Large-cap Healthcare median P/E29.7x
Full factsheet
The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Narrow).
Read it in the browser Download (PDF)All fundamentals · 140 measures in 13 categories
Percentile = where STE sits among 7 scored companies in Medical - Specialties (0 = lowest value, 100 = highest). It is a position, not a grade.ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)
Valuation
| Measure | STE | Industry percentile |
|---|---|---|
| P/E (TTM) | 27.0x | |
| PEG (P/E ÷ 3-yr EPS CAGR) | 0.30 | |
| Price / sales | 3.6x | 50th |
| Price / book | 3.0x | 33rd |
| Price / tangible book | 14.2x | 100th |
| Price / free cash flow | 23.5x | 50th |
| Price / operating cash flow | 16.8x | 50th |
| Enterprise value | $23.3B | 83rd |
| EV / sales | 3.9x | 50th |
| EV / EBITDA | 14.3x | |
| EV / EBIT | 20.4x | |
| EV / free cash flow | 25.1x | 50th |
| Earnings yield | 3.7% | 100th |
| FCF yield | 4.3% | 67th |
| Operating cash flow yield | 5.9% | 67th |
| Graham number (per share) | $116.71 |
Profitability (TTM)
| Measure | STE | Industry percentile |
|---|---|---|
| Gross margin | 44.4% | 0th |
| EBITDA margin | 27.0% | 100th |
| Operating margin | 18.9% | 100th |
| EBIT margin | 18.9% | 100th |
| Net margin | 13.3% | 83rd |
| NOPAT margin | 14.0% | 100th |
| FCF margin | 15.3% | 67th |
| Operating cash flow margin | 21.3% | 83rd |
| R&D / revenue | 1.9% | 0th |
| SG&A / revenue | 17.5% | 0th |
| Stock comp / revenue | 1.0% | 50th |
| Effective tax rate | 25.8% | 83rd |
Returns on capital
| Measure | STE | Industry percentile |
|---|---|---|
| ROE (on average equity) | 11.4% | 83rd |
| ROA | 7.6% | 83rd |
| ROIC | 9.7% | 83rd |
| ROCE | 12.1% | 100th |
| Return on tangible assets | 10.8% | 100th |
| Cash ROIC (OCF / invested capital) | 14.7% | 67th |
| Gross profitability (GP / assets) | 25.0% | 50th |
| ROIC, 3-yr average | 6.1% | 100th |
| ROIC, 5-yr average | 5.3% | 80th |
| ROE, 5-yr average | 6.9% | 100th |
| Incremental ROIC | 163.0% | 100th |
Growth
| Measure | STE | Industry percentile |
|---|---|---|
| Revenue growth (TTM YoY) | 8.4% | 80th |
| Revenue growth (QoQ) | -6.0% | 0th |
| Revenue CAGR, 3 yr | 6.6% | 60th |
| Revenue CAGR, 5 yr | 12.1% | 40th |
| Gross profit CAGR, 3 yr | 7.3% | 80th |
| Operating income CAGR, 3 yr | 54.8% | |
| Net income growth (TTM YoY) | 24.5% | |
| Net income CAGR, 3 yr | 89.0% | |
| EPS growth (TTM YoY) | 25.6% | |
| EPS CAGR, 3 yr | 89.8% | |
| EPS CAGR, 5 yr | 21.2% | |
| FCF growth (TTM YoY) | 1.8% | |
| FCF CAGR, 3 yr | 23.3% | |
| Operating cash flow CAGR, 3 yr | 16.9% | |
| Book value CAGR, 3 yr | 5.8% | 80th |
| Dividend CAGR, 3 yr | 3.7% | |
| Sustainable growth rate | 7.9% |
Margin history & stability
| Measure | STE | Industry percentile |
|---|---|---|
| Gross margin, 3-yr average | 43.9% | 0th |
| Operating margin, 3-yr average | 17.6% | 100th |
| Net margin, 3-yr average | 11.0% | 100th |
| FCF margin, 3-yr average | 14.6% | 60th |
| Revenue stability (0-1) | 0.94 | 80th |
| Earnings stability (0-1) | 0.63 | 100th |
| Margin stability (0-1) | 0.99 | 100th |
Liquidity (latest quarter)
| Measure | STE | Industry percentile |
|---|---|---|
| Cash & short-term investments | $482.3M | 83rd |
| Net cash (− = net debt) | −$1.6B | 33rd |
| Working capital | $1.2B | 83rd |
| Current ratio | 1.91 | 17th |
| Quick ratio | 1.35 | 33rd |
| Cash ratio (cash + ST investments / current liabilities) | 0.38 | 17th |
| Defensive interval (days) | 354 days | 50th |
Leverage & solvency (latest quarter)
| Measure | STE | Industry percentile |
|---|---|---|
| Total debt | $2.0B | 67th |
| Debt / equity | 0.28 | 67th |
| Net debt / equity | 0.22 | 67th |
| Debt / assets | 19.0% | 67th |
| Debt / capital | 22.1% | 67th |
| Debt / EBITDA | 1.25 | |
| Net debt / EBITDA | 0.96 | |
| Interest coverage (EBIT / interest) | 18.8x | 100th |
| Cash interest coverage | 21.3x | 100th |
| Debt payback (years of OCF) | 1.6 yrs | 25th |
| Liabilities / assets | 32.7% | 33rd |
| IS credit model rating | AA | |
| Implied credit spread (bps) | 80 | 0th |
Efficiency
| Measure | STE | Industry percentile |
|---|---|---|
| Asset turnover | 0.57 | 83rd |
| Fixed asset turnover | 2.78 | 33rd |
| Inventory turnover | 5.0 | 100th |
| Receivables turnover | 6.2 | 33rd |
| Days sales outstanding | 59 days | 67th |
| Days inventory outstanding | 74 days | 0th |
| Days payables outstanding | 35 days | 17th |
| Cash conversion cycle (days) | 98 days | 0th |
| Capex / revenue | 6.0% | 80th |
| Capex / depreciation | 0.74 | 60th |
| Operating expense ratio | 26.7% | 0th |
Cash flow & earnings quality
| Measure | STE | Industry percentile |
|---|---|---|
| Operating cash flow / net income | 1.60 | |
| FCF / net income | 1.15 | |
| FCF / operating cash flow | 71.8% | |
| Capex / operating cash flow | 28.2% | |
| Accruals ratio | -4.6% | 67th |
| Sloan accruals ratio | -4.3% | 50th |
| Earnings quality score (0-1) | 1.00 |
Scores & forensic checks
| Measure | STE | Industry percentile |
|---|---|---|
| IS score | 69 | 100th |
| IS profitability | 53 | 83rd |
| IS growth | 63 | 80th |
| IS value | 51 | 100th |
| IS momentum | 90 | 100th |
| IS risk (safety) | 100 | 67th |
| IS quality | 81 | 100th |
| IS balance sheet | 72 | 67th |
| IS earnings quality | 74 | 83rd |
| IS cash flow | 63 | 83rd |
| Piotroski F-score (0-9) | 8 | 83rd |
| Altman Z-score | 5.0 | 83rd |
| Beneish M-score | −2.47 | 80th |
| Ohlson O-score | −9.77 | 17th |
| IS credit score | 88 | 100th |
Size (TTM)
| Measure | STE | Industry percentile |
|---|---|---|
| Market cap | $21.7B | 83rd |
| Revenue | $6.0B | 83rd |
| EBITDA | $1.6B | 83rd |
| Net income | $805.1M | 100th |
| Free cash flow | $925.6M | 83rd |
| Total assets | $10.7B | 83rd |
| Shareholders' equity | $7.2B | 83rd |
| Employees | 17,937 | 83rd |
Insider transactions, last 6 months
Form 4 · most recent 12| Date | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-01 | Burton Karen L Sr. Vice Pres., CFO |
Tax withholding | 228 | — | — | 12,956 |
| 2026-08-12 | Sohi Mohsen Director |
Option exercise | 4,058 | $86.23 | $349,921 | 28,363 |
| 2026-08-12 | Sohi Mohsen Director |
Open-market sale | 4,058 | $235.78 | $956,795 | 24,305 |
| 2026-08-12 | Sohi Mohsen Director |
Option exercise | 4,058 | $86.23 | $349,921 | 0 |
| 2026-08-10 | Boulud Pierre Director |
Award / grant | 1,025 | — | — | 1,392 |
| 2026-08-10 | Alegria Esther M. Director |
Award / grant | 1,506 | $238.91 | $359,798 | 1,506 |
| 2026-08-10 | Alegria Esther M. Director |
Award / grant | 512 | — | — | 3,408 |
| 2026-08-10 | Sohi Mohsen Director |
Award / grant | 1,099 | $238.91 | $262,562 | 1,099 |
| 2026-08-10 | Sohi Mohsen Director |
Award / grant | 1,229 | — | — | 8,979 |
| 2026-08-10 | Shapiro Louis Director |
Award / grant | 1,025 | — | — | 2,000 |
| 2026-08-10 | Shah Nirav R Director |
Award / grant | 1,506 | $238.91 | $359,798 | 1,506 |
| 2026-08-10 | Shah Nirav R Director |
Award / grant | 512 | — | — | 7,015 |
Shares acquired vs disposed, by month
acquired disposed · all Form 4 typesBy transaction type, 6 months
| Type | Direction | Filings | Shares | Value |
|---|---|---|---|---|
| Award / grant | Acquired | 32 | 227,385 | $40.0M |
| Open-market sale | Disposed | 5 | 11,386 | $2.5M |
| Option exercise | Disposed | 4 | 11,686 | $903,692 |
| Option exercise | Acquired | 3 | 11,620 | $889,848 |
| Tax withholding | Disposed | 24 | 11,890 | $2.5M |
| — | Disposed | 1 | 0 | — |
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.
Form 144 notices
12 months: 10 notices · 43,638 shares · $10.8M| Filed | Filer | Shares proposed | Est. proceeds |
|---|---|---|---|
| 2026-08-18 | Breeden Richard C | 4,110 | $953,114 |
| 2026-08-12 | Sohi Mohsen | 4,058 | $956,779 |
| 2026-06-15 | Zangerle John Adam | 1,419 | $296,968 |
| 2026-06-05 | Carestio Daniel A | 1,374 | $291,288 |
A Form 144 is notice of a proposed sale, not a confirmed one.
Congress trades
12 months: House 40 trades (20 purchases) · Senate 0 (0 purchases)| Traded | Member | Chamber | Type | Amount | Disclosed |
|---|---|---|---|---|---|
| 2026-09-25 | Ro Khanna | House | Sale | $1,001 - $15,000 | 2026-10-09 |
| 2026-09-15 | Kevin Hern | House | Sale | $15,001 - $50,000 | 2026-09-28 |
| 2026-09-15 | Kevin Hern | House | Sale (Full) | $15,001 - $50,000 | 2026-09-25 |
| 2026-09-11 | Ro Khanna | House | Purchase | $1,001 - $15,000 | 2026-10-09 |
| 2014-07-23 | Susan M. Collins | Senate | Sale (Full) | $1,001 - $15,000 | 2015-07-20 |
| 2014-07-23 | Susan M. Collins | Senate | Sale (Full) | $1,001 - $15,000 | 2015-07-19 |
| 2014-07-23 | Susan M. Collins | Senate | Sale (Full) | $1,001 - $15,000 | 2014-08-14 |
| 2014-07-23 | Susan M. Collins | Senate | Sale (Full) | $1,001 - $15,000 | 2014-08-13 |
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.
Largest 13F holders
| Manager | Shares | Value | % of shares out |
|---|---|---|---|
| None on file. | |||
Institutional ownership by quarter
% of shares held by 13F filers
Number of 13F filers holding
Holder changes by quarter
| Quarter | Holders | Ownership | New | Increased | Reduced | Closed |
|---|---|---|---|---|---|---|
| None on file. | ||||||
Schedule 13D / 13G filers
| Filed | Form | Filer | % of class | Shares |
|---|---|---|---|---|
| 2026-05-12 | SCHEDULE 13G | STATE STREET CORPORATION | 5.1% | 4,995,259 |
| 2026-04-29 | SCHEDULE 13G | Vanguard Portfolio Management | 5.0% | 4,962,018 |
| 2026-03-27 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 |
| 2025-11-04 | SCHEDULE 13G/A | Massachusetts Financial Services Company | 4.9% | 4,846,124 |
Required above 5% of a class; 13G is the passive form.
ETFs with the largest holding
| ETF | Weight in fund | Holding value |
|---|---|---|
| VITSX | 0.03% | $649.0M |
| VTI | 0.03% | $649.0M |
| VSMPX | 0.03% | $649.0M |
| VTSAX | 0.03% | $649.0M |
| VFFSX | 0.03% | $537.8M |
| VOO | 0.03% | $537.8M |
Share structure
Shares outstanding97,500,100
Float97,167,722
Free float99.7%
Income statement
Fiscal years, USD| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|
| Revenue | $4.2B | $4.5B | $5.1B | $5.5B | $5.9B |
| Cost of revenue | $2.3B | $2.6B | $2.9B | $3.1B | $3.3B |
| Gross profit | $1.9B | $2.0B | $2.2B | $2.4B | $2.6B |
| R&D | $86.7M | $98.5M | $103.7M | $107.6M | $112.9M |
| SG&A | $1.3B | $1.1B | $1.3B | $1.3B | $1.4B |
| Operating income | $477.8M | $791.1M | $836.1M | $866.6M | $1.1B |
| EBITDA | $1.0B | $1.3B | $1.4B | $1.4B | $1.6B |
| Pretax income | $366.8M | $680.3M | $702.8M | $796.2M | $1.0B |
| Income tax | $82.3M | $124.1M | $149.5M | $184.7M | $262.2M |
| Net income | $243.9M | $107.0M | $378.2M | $614.6M | $785.1M |
| EPS, diluted | $2.48 | $1.07 | $3.81 | $6.20 | $7.93 |
| Diluted shares | 98.3M | 100.2M | 99.4M | 99.1M | 98.7M |
Balance sheet
| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|
| Cash & short-term investments | $348.3M | $208.4M | $207.0M | $171.7M | $439.6M |
| Receivables | $799.0M | $865.0M | $1.0B | $1.0B | $1.1B |
| Inventory | $575.0M | $604.4M | $674.5M | $581.3M | $631.8M |
| Total current assets | $1.9B | $2.0B | $2.9B | $2.0B | $2.4B |
| PP&E, net | $1.7B | $1.8B | $1.9B | $2.1B | $2.3B |
| Goodwill & intangibles | $7.7B | $6.0B | $6.2B | $6.0B | $5.8B |
| Total assets | $11.4B | $10.8B | $11.1B | $10.1B | $10.7B |
| Accounts payable | $225.7M | $264.2M | $251.7M | $280.8M | $338.8M |
| Total current liabilities | $922.2M | $861.8M | $931.1M | $1.0B | $1.1B |
| Long-term debt | $2.9B | $3.0B | $3.1B | $1.9B | $1.8B |
| Total liabilities | $4.9B | $4.7B | $4.7B | $3.5B | $3.5B |
| Shareholders' equity | $6.5B | $6.1B | $6.3B | $6.6B | $7.2B |
Cash flow statement
Outflows are negative| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|
| Net income | $242.9M | $105.8M | $380.1M | $616.1M | $785.1M |
| Depreciation & amortization | $553.1M | $552.9M | $565.2M | $476.2M | $486.5M |
| Stock-based compensation | $57.7M | $39.0M | $56.5M | $57.4M | $61.7M |
| Change in working capital | −$149.3M | −$250.0M | −$146.1M | $66.5M | $27.1M |
| Operating cash flow | $684.8M | $756.9M | $973.3M | $1.1B | $1.3B |
| Capital expenditure | −$287.6M | −$362.0M | −$360.3M | −$370.1M | −$369.0M |
| Free cash flow | $397.2M | $395.0M | $612.9M | $778.0M | $972.4M |
| Investing cash flow | −$666.6M | −$383.3M | −$887.4M | $388.8M | −$512.5M |
| Net debt issued / repaid | $372.2M | −$6.2M | $121.5M | −$1.2B | −$122.0M |
| Buybacks | −$55.8M | −$308.6M | −$11.8M | −$211.3M | −$235.5M |
| Dividends paid | −$163.2M | −$183.5M | −$200.6M | −$219.9M | −$241.8M |
Ratio history
Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|
| Gross margin | 44.0% | 43.6% | 43.1% | 44.0% | 44.2% |
| Operating margin | 9.3% | 5.4% | 17.8% | 15.9% | 18.6% |
| Net margin | 5.3% | 2.2% | 7.8% | 11.3% | 13.2% |
| FCF margin | 8.7% | 8.0% | 12.7% | 14.3% | 16.4% |
| ROE | 4.7% | 1.7% | 6.1% | 9.5% | 11.3% |
| ROIC | 3.5% | 2.0% | 7.1% | 7.7% | 9.4% |
| ROA | 2.7% | 1.0% | 3.5% | 5.8% | 7.5% |
| Debt / equity | 0.50 | 0.53 | 0.54 | 0.33 | 0.29 |
| Interest coverage | 4.5x | 2.4x | 6.0x | 10.2x | 18.2x |
| Current ratio | 2.04 | 2.33 | 3.08 | 1.96 | 2.09 |
| Revenue growth | +47.5% | +8.1% | −2.5% | +12.9% | +8.7% |
| EPS growth | −47.4% | −55.6% | +256.0% | +62.7% | +27.8% |
| P/E at year end | 96.3x | 173.3x | 57.7x | 36.1x | 27.8x |
| EV / EBITDA at year end | 27.6x | 26.3x | 17.4x | 17.8x | 14.7x |
| FCF yield at year end | 1.69% | 2.13% | 2.81% | 3.50% | 4.47% |
| Dividend payout | 66.9% | 171.4% | 53.0% | 35.8% | 30.9% |
Revenue by segment
| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|
| Product | $2.6B | $2.8B | $2.8B | $2.9B | $3.1B |
| Service | $2.0B | $2.2B | $2.4B | $2.6B | $2.9B |
Revenue by region · FY2026
UNITED STATES$4.3B · 73%
Other foreign locations$1.5B · 25%
IRELAND$108.5M · 2%
Street estimates by fiscal year
Next report 2026-11-04 · consensus EPS $2.68 · these are analysts' numbers, not ours| Fiscal year | Revenue (mean) | Revenue range | EPS (mean) | EPS range | Analysts | P/E on mean EPS |
|---|---|---|---|---|---|---|
| 2026 | $5.9B | $5.9B – $6.0B | $10.20 | $10.19 – $10.21 | 5 | 21.8x |
| 2027 | $6.4B | $6.4B – $6.4B | $11.21 | $10.98 – $11.34 | 5 | 19.9x |
| 2028 | $6.8B | $6.7B – $6.8B | $12.25 | $12.23 – $12.28 | 5 | 18.2x |
Reported vs expected, every quarter on file
| Reported | EPS expected | EPS actual | EPS surprise | Revenue expected | Revenue actual | Revenue surprise |
|---|---|---|---|---|---|---|
| 2026-08-05 | $2.49 | $2.59 | +4.0% | $1.5B | $1.5B | +0.3% |
| 2026-05-11 | $2.85 | $2.83 | −0.7% | $1.6B | $1.6B | −0.4% |
| 2026-02-04 | $2.53 | $2.53 | 0.0% | $1.5B | $1.5B | +1.0% |
| 2025-11-05 | $2.35 | $2.47 | +5.1% | $1.4B | $1.5B | +2.0% |
| 2025-08-06 | $2.26 | $2.34 | +3.5% | $1.4B | $1.4B | +2.1% |
| 2025-05-14 | $2.60 | $2.74 | +5.4% | $1.5B | $1.5B | +0.8% |
| 2025-02-05 | $2.33 | $2.32 | −0.4% | $1.4B | $1.4B | −0.8% |
| 2024-11-06 | $2.12 | $2.14 | +0.9% | $1.3B | $1.3B | −0.1% |
| 2024-08-06 | $1.98 | $2.03 | +2.5% | $1.3B | $1.3B | +0.6% |
| 2024-05-08 | $2.35 | $2.41 | +2.6% | $1.4B | $1.4B | +0.6% |
| 2024-02-07 | $2.17 | $2.22 | +2.3% | $1.3B | $1.4B | +3.5% |
| 2023-11-07 | $2.05 | $2.03 | −1.0% | $1.3B | $1.3B | +3.3% |
| 2023-08-01 | $1.86 | $2.00 | +7.5% | $1.3B | $1.3B | −0.7% |
| 2023-05-10 | $2.15 | $2.30 | +7.0% | $1.3B | $1.4B | +8.8% |
| 2023-02-08 | $2.22 | $2.02 | −9.0% | $1.3B | $1.2B | −4.5% |
| 2022-11-09 | $2.00 | $1.99 | −0.5% | $1.2B | $1.2B | −1.8% |
| 2022-08-02 | $1.90 | $1.90 | 0.0% | $1.2B | $1.2B | −5.5% |
| 2022-05-11 | $2.00 | $2.04 | +2.0% | $1.2B | $1.2B | +3.1% |
| 2022-02-08 | $1.95 | $2.12 | +8.7% | $1.2B | $1.2B | +1.2% |
| 2021-11-02 | $1.83 | $1.99 | +8.7% | $1.2B | $1.2B | +3.9% |
| 2021-08-09 | $1.50 | $1.76 | +17.3% | $968.4M | $968.4M | 0.0% |
| 2021-05-18 | $1.80 | $1.63 | −9.4% | $874.4M | $873.5M | −0.1% |
| 2021-02-02 | $1.52 | $1.73 | +13.8% | $697.2M | $808.9M | +16.0% |
| 2020-11-02 | $1.27 | $1.48 | +16.5% | $74.8M | $756.1M | +910.5% |
Off-exchange (dark pool) volume, weekly
FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)| Week of | Notional | Shares | Trades |
|---|---|---|---|
| 2026-08-31 | $142.7M | 621,966 | 28,535 |
| 2026-08-24 | $161.4M | 684,789 | 26,680 |
| 2026-08-17 | $235.8M | 1,004,788 | 33,677 |
| 2026-08-10 | $213.3M | 902,141 | 35,210 |
| 2026-08-03 | $364.3M | 1,578,437 | 45,402 |
| 2026-07-27 | $299.6M | 1,311,801 | 40,623 |
Short-sale share of off-exchange volume
daily 20-day average| Date | Short share | Short volume | Total volume |
|---|---|---|---|
| 2026-10-15 | 42.5% | 150,993 | 355,126 |
| 2026-10-14 | 47.4% | 95,163 | 200,771 |
| 2026-10-13 | 59.4% | 103,333 | 173,947 |
| 2026-10-12 | 72.9% | 205,548 | 282,112 |
| 2026-10-09 | 67.8% | 152,621 | 225,098 |
| 2026-10-08 | 56.3% | 103,732 | 184,250 |
| 2026-10-07 | 51.0% | 116,239 | 227,947 |
| 2026-10-06 | 55.0% | 142,953 | 259,732 |
| 2026-10-05 | 52.0% | 147,317 | 283,436 |
| 2026-10-02 | 69.4% | 208,033 | 299,722 |
A daily flow measure from FINRA, not short interest.
Seasonality
Average return by calendar month| Month | Avg return | Up years | Years |
|---|---|---|---|
| Jan | +0.8% | 60% | 20 |
| Feb | +0.3% | 50% | 20 |
| Mar | +2.2% | 76% | 21 |
| Apr | −0.1% | 45% | 20 |
| May | +4.0% | 70% | 20 |
| Jun | +0.9% | 50% | 20 |
| Jul | +2.2% | 70% | 20 |
| Aug | +0.8% | 55% | 20 |
| Sep | +0.4% | 60% | 20 |
| Oct | +2.2% | 60% | 20 |
| Nov | +2.0% | 70% | 20 |
| Dec | −0.5% | 50% | 20 |
History, not a forecast.
Indicators
as of 2026-10-16RSI 1462.1
MFI63.8
ADX26.3
Stochastic %K / %D83.6 / 81.3
Williams %R-20.0
CCI189
TSI / signal4.7 / -13.8
Chaikin money flow0.22
ATR$4.79
Bollinger width9.2%
Volume vs 20-day avg0.74x
SupertrendUp
Moving averages and bands
level (price vs level)SMA 20$212.43 (+4.8%)
SMA 50$221.22 (+0.7%)
SMA 200$226.08 (−1.5%)
EMA 21$215.45 (+3.3%)
EMA 50$217.31 (+2.5%)
EMA 200$224.02 (−0.6%)
Bollinger upper$222.24 (+0.2%)
Bollinger lower$202.61 (+9.9%)
Parabolic SAR$211.26 (+5.4%)
Open the live chart, 110+ indicatorsAbout STERIS plc
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.
https://www.steris.com
Key executives
| Name | Title | Pay | Born |
|---|---|---|---|
| Daniel A. Carestio | President, Chief Executive Officer & Director | $2.8M | 1973 |
| Andrew Xilas | Senior Vice President & GM of Dental | $1.4M | 1965 |
| John Adam Zangerle | Senior Vice President, General Counsel & Secretary | $1.1M | 1967 |
| Karen L. Burton | Senior Vice President, Chief Financial Officer & Chief Accounting Officer | $1.0M | 1968 |
| Cary L. Majors | Senior Vice President & President of Healthcare | $1.0M | 1975 |
| Mary Clare Fraser | SVP & Chief Human Resources Officer | $854,779 | 1970 |
| Julie Winter | Vice President of Investor Relations & Corporate Communications | — | — |
| Kenneth E. Kohler | Senior Vice President & GM of AST | — | 1963 |
Executive pay, latest proxy
| Executive | Year | Salary | Stock awards | Incentive | Total |
|---|---|---|---|---|---|
| Daniel A. Carestio President and CEO | 2026 | $1.1M | $4.3M | $1.7M | $11.5M |
| Karen L. Burton Senior Vice President and Chief Financial Officer | 2026 | $530,762 | $1.0M | $491,493 | $3.2M |
| J. Adam Zangerle Senior Vice President, General Counsel, and Company Secretary | 2026 | $570,417 | $913,947 | $538,815 | $3.0M |
| Cary L. Majors Senior Vice President and President, Healthcare | 2026 | $537,115 | $711,010 | $473,535 | $2.5M |
| Michael J. Tokich Senior Financial Advisor | 2026 | $511,409 | $540,923 | $616,644 | $2.2M |
| Mary Clare Fraser Senior Vice President and Chief Human Resources Officer | 2026 | $461,615 | $609,542 | $377,902 | $2.1M |
Employees
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| 2026-09-04 | $0.69 | 2026-09-25 |
| 2026-06-08 | $0.63 | 2026-06-26 |
| 2026-02-17 | $0.63 | 2026-03-19 |
| 2025-11-18 | $0.63 | 2025-12-18 |
| 2025-09-04 | $0.63 | 2025-09-26 |
| 2025-06-10 | $0.57 | 2025-06-26 |
| 2025-02-20 | $0.57 | 2025-03-21 |
| 2024-11-19 | $0.57 | 2024-12-19 |
Moat model
Narrow · Efficient Scale · 2026-06-30Cost advantage79
Intangibles31
Switching costs50
Network effect60
Efficient scale85
Our component scores (0-100) and overall 57.8; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17